**ABSTRACT**

**Introduction** Head and neck cancer squamous cell carcinoma (HNSCC) is the sixth most common cancer internationally. Established risk factors include smoking, alcohol and presence of human papillomavirus (HPV). The incidence rate of new disease continues to rise, despite falls in alcohol consumption and a reduction in smoking, the rising rates are unlikely to be solely attributed to HPV status alone. Obesity and its associated conditions such as type 2 diabetes (T2D) are implicated in the risk and progression of a variety of cancers, but there is paucity of evidence regarding its role in HNSCC.

**Methods and analysis** A systematic review of cohort studies, reporting a risk of incident HNSCC, will be included. A systematic search strategy has been developed, multiple databases will be searched from January 1966 to November 2021, including Cochrane Library, OVID SP versions of Medline and EMBASE. The primary outcome will be incident HNSCC based on exposures of T2D, obesity, dyslipidaemia and hypertension as defined by the WHO. A combined risk effect across studies will be calculated using meta-analysis, although depending on the heterogeneity in study design, exposure and outcome reporting this may not be possible.

**Ethics and dissemination** No ethical approval is required for this systematic review. The review will be published in a relevant peer-review journal and findings will be presented at scientific meetings in both poster and oral presentation form.

**PROSPERO registration number details** This study has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) with study registration number CRD42021250520. This protocol has been developed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidance statement.

**INTRODUCTION**

Head and neck cancer squamous cell carcinoma (HNSCC), which includes cancer of the oral cavity, oropharynx, hypopharynx and larynx, is the world’s sixth most common cancer, with the highest incidence in men and those over 70 years old. Established risk factors include smoking, alcohol and the human papillomavirus (HPV), which has mainly been linked to oropharyngeal cancer. Despite the significant reduction in smoking, and a fall in alcohol consumption, in the UK over the previous two decades, incidence rates of head and neck cancers have continued to rise by around a third. Given this potentially changing aetiology, further exploration of less well known risk factors is warranted to target prevention and identify patients with early disease. People living with obesity and associated conditions, such as type 2 diabetes (T2D), have an increased risk of developing certain cancers (eg, liver and pancreas), but the epidemiological evidence surrounding HNSCC is not conclusive. Recent studies have demonstrated elevated glucose levels before or at the time of diagnosis, which may play a role in the pathogenesis and progression of cancer. Carcinogenesis in HNSCC is driven by diverse signalling pathways; however, little is known about the role of metabolism, despite metabolic reprogramming being a recognised hallmark of cancer.
T2D is a common condition characterised by insulin resistance and hyperglycaemia, which results in whole-body metabolic dysregulation. In 2015, the estimated worldwide diabetes prevalence for adults was predicted to rise to 642 million by 2040. In addition, public health strategies have not successfully addressed the current ‘obesity pandemic’. One large pooled analysis demonstrated a weak positive association between T2D and HNSCC (OR 1.09; 95% CI: 0.95 to 1.24), which was stronger among those who never smoked cigarettes (OR 1.59; 95% CI: 1.22 to 2.07). While obesity is a potent risk factor for T2D, the relationship between body mass index (BMI) and HNSCC is not straightforward, with both positive and inverse associations observed. Another study found that a positive association with BMI was only observed in never smokers. In the largest study to date, waist circumference and waist-to-hip ratio were positively associated with higher HNSCC risk, regardless of smoking status. Metabolic syndrome has been described as a clustering of disorders including obesity, hypertension, hyperglycaemia and dyslipidaemia. A moderate inverse association has been observed between metabolic syndrome and HNSCC (OR 0.81; 95% CI: 0.78 to 0.85), but again these results were modified by tobacco use. Treatment for these conditions using medications such as statins, or metformin, may also reduce the risk of developing HNSCC. Given the growing pandemic of metabolic disorders, understanding how these alterations affect the risk of carcinogenesis may identify those who are at high risk. This could drive targeted prevention, earlier detection and perhaps the identification or repurposing of drug targets for treatment in HNSCC.

Rationale
The complex metabolic changes associated with T2D, obesity, dyslipidaemia and hypertension may alter the risk of certain cancers, but the evidence for head and neck cancer is inconclusive. This study aims to identify, collate and synthesise all relevant studies including adult participants, to determine whether the risk of developing incident HNSCC is influenced by T2D, obesity, dyslipidaemia and hypertension, using relevant effect measures (eg, OR or risk ratios (RR)). Where available, we will further stratify by subsite (ie, oral cavity, oropharynx, hypopharynx and larynx), as well as by HPV status.

METHODS

Research question
Do metabolic disorders affect the risk of developing head and neck cancer?

Study design
Randomised controlled trials are informative for assessing causal effects; however, due to the nature of the exposures in this study, inclusion of this design is not feasible. Therefore, we will focus on observational (eg, cohort studies) reporting the risk of metabolic disorders on incident HNSCC.

Eligibility criteria
Population: participants over 18 years old, of either sex, from any ethnic background.

Exposures (1) T2D, (2) obesity, (3) dyslipidaemia and (4) hypertension. These will be collectively described as ‘metabolic disorders’.

Comparison: participants who have not been diagnosed with the afore-mentioned metabolic disorders.

Outcome: incident HNSCC.

The study will report in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and has been pre-registered on International Prospective Register of Systematic Reviews (PROSPERO) in 2021.

Search strategy
A systematic search strategy (online supplemental table 1) has been formulated by clinicians, scientific researchers and a specialist librarian for surgery, head and neck and medicine. Medical Subject Headings and keywords will be iteratively combined with the Boolean operators AND, OR and NOT. Multiple databases will be searched from January 1966 to November 2021, including OVID SP versions of Medline and EMBASE, using the formulated search strategy (online supplemental table 1). Preprint servers including medRxiv and bioRxiv will also be searched. In addition, the following electronic bibliographic databases will be searched: Cochrane Library, ETHOS, Google Scholar, Open Grey and ClinicalTrials.gov, to identify articles from the grey literature and conference proceedings using a modified search strategy (online supplemental table 2). References extracted from the full-length articles will be reviewed to identify other publications of interest. Duplicate articles will be removed using Covidence.

Data management
The results from searches will be imported into Covidence software, to improve reference management and workflow. This will also populate a PRISMA flow diagram.

Data screening and extraction
All titles and abstracts will be screened by two authors AG and CR, with conflicts resolved by MG. Screening records and decisions will be kept in Covidence. Data will be extracted from titles that meet the inclusion criteria (table 1). The data extraction form (Online supplemental table 3) will be piloted using five included titles with AG, CR and MG independently completing data extraction. If amendments are necessary, they will be performed at this point, with consensus approval required prior to final use of the form. Subsequent to this, CR and MG will double data extract independently for each title, any disagreements will be discussed among AG, CR and MG with consensus approval required.

Gormley A, et al. BMJ Open 2022;12:e058392. doi:10.1136/bmjopen-2021-058392
Exposure definitions

1. The WHO defines T2D as a chronic disease that occurs when the body cannot effectively use the insulin it produces and is largely the result of excess body weight and physical inactivity. A diagnosis of T2D was defined as symptoms such as polyuria or polydipsia, plus:25 26:
   - A random blood plasma glucose concentration ≥11.1 mmol/L.
   - A fasting plasma glucose concentration ≥7.0 mmol/L (whole blood ≥6.1 mmol/L).
   - Two-hour plasma glucose concentration ≥11.1 mmol/L, two hours after 75 g anhydrous glucose in an oral glucose tolerance test.
   - Glycated haemoglobin (HbA1c) 6.5% or more (48 mmol/mol and above).

Relevant International Classification of Disease (ICD) codes used to define T2D will also be acceptable.

2. The WHO definition of BMI of 30 or above must have been used to define obesity.27 BMI if calculated from self-reported height and weight or taken from medical records or measured at baseline will be acceptable.

3. Dyslipidaemia was classified as serum total cholesterol, low-density lipoprotein cholesterol, triglycerides, apolipoprotein B or lipoprotein(a) concentrations above the 90th percentile, or high-density lipoprotein cholesterol or apolipoprotein concentrations below the 10th percentile for the general population.28 Relevant ICD codes used to define dyslipidaemia will also be acceptable.

4. The WHO definition of hypertension as:29
   - A systolic blood pressure reading of ≥140 mm Hg.
   - A diastolic blood pressure readings on both days of ≥90 mm Hg, must have been used.

Relevant ICD codes used to define hypertension will also be acceptable.

Outcome definitions

All diagnoses of incident HNSCC included in this study should have been confirmed by histology by a trained pathologist. Acceptable cancer diagnosis may be reported using ICD codes.30 Cancer cases for the disease of interest have the following ICD-10 codes: oral cavity (C02.0–C02.9, C03.0–C03.9, C04.0–C04.9, C05.0–C06.9) oropharynx (C01.9, C02.4, C09.0–C10.9), hypopharynx (C13.0–C13.9), overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code (other).

Older versions of ICD code, for example, ICD-8 and ICD-9 were also accepted. With respect to HPV diagnosis, only high-risk subtypes HPV16, 18, 31, and 33 will be included. These should be detected using HPV-DNA via PCR and/or in situ hybridisation examination, usually used in combination with immunohistochemistry for p16.

Data analysis and synthesis

The analysis and synthesis process will be performed in two phases. The first phase consists of estimating the effect of each metabolic disorder (T2D, obesity, dyslipidaemia and hypertension) on incident HNSCC separately for each included study. Effects should be reported as HR, standardised incidence ratio, OR or RR, with 95% CIs or in a format that will enable us to calculate these.

The second phase will focus on estimating the combined effect across studies using meta-analysis, using metan software in Stata (Stata Statistical Software: Release V16. College Station, Texas, USA: StataCorp LLC). Summary effects with their corresponding 95% CIs will be derived with the method of DerSimonian and Laird.31 This will be performed separately for each metabolic disorder. The analysis will yield information about the heterogeneity of effects across studies, using Cochran’s Q test and Higgins’ I² statistic. Due to the heterogeneity in study
design, exposure definition and outcome reporting in the included studies, meta-analysis may not be reasonable. If appropriate, to further explore the sources of heterogeneity if present, meta-regression analyses will be performed according to age, geographic location, year of publication, methods of exposure assessment, risk of bias score, length of follow-up, the number of cases and adjustment for confounding factors including smoking and alcohol use. Small study effects, which may reflect publication bias, study quality or other sources of heterogeneity, will be assessed using funnel plots and Egger’s regression asymmetry tests.

**Subgroup analyses**

Where possible, we will stratify by oral, oropharyngeal, hypopharyngeal and laryngeal subsite and by HPV status as post-hoc analyses, to determine if effects seen are specific to a particular anatomical region or associated with specific tumour types.

**Risk of bias in studies**

Two authors will independently extract the relevant risk factor information during data extraction using a preliminary version of the Risk of Bias in Non-randomised Studies—of Exposures (ROBINS-E) tool (https://www.bristol.ac.uk/population-health-sciences/centres/cresyda/barr/riskofbias/robins-e/). The ROBINS-E tool aims to assess the result of interest from an observational study for risk of bias, where that study is designed to assess the effect of exposure on outcome. Disagreements will be recorded and discussed with a third author for resolution. This assessment will be used in evaluating the strength of evidence from the included studies.

**Amendments**

Any amendments to the initial protocol will be included in an update to the PROSPERO record, including information on amendment type, reasoning and a timestamp. Deviation from this protocol will be described in the full systematic review paper.

**DISSEMINATION**

This systematic review will be published in a relevant peer-reviewed journal and findings from this work may be presented at scientific meetings (both poster and oral presentations).

**Author affiliations**

1. Bristol Dental School, Faculty of Health Sciences, University of Bristol, Bristol, UK
2. Bristol Dental Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
3. School of Dentistry, Cardiff University, Cardiff, UK
4. Population Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, UK
5. MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK
6. Library and Information Services, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
7. School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol, UK

**REFERENCES**

1. Cancer Research UK (CRUK). Head and neck cancer statistics 2019, 2019. Available: [https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Two](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Two) [Accessed 13 Sep 2021].
2. Thomas SJ, Penfold CM, Waylen A, et al. The changing aetiology of head and neck squamous cell cancer: a tale of three cancers? *Cin Otolaryngol* 2018;43:999–1003.
3. Office for national statistics, data for 1974 onwards; office for national statistics. Adult Smoking habits in Great Britain 2020/2020. [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain)
4. Office for national statistics. adult drinking habits in Great Britain 2017, 2021. Available: [https://www.ons.gov.uk/peoplepopulationandcommunity](https://www.ons.gov.uk/peoplepopulationandcommunity)

**Contributors**

AG and CR jointly contributed to the development of the protocol and the drafting, writing and editing of this manuscript. FS contributed to the development of the study and editing of the manuscript. JH contributed to the development of the search strategy. BM, EG, EV, RR and JH contributed to the development of this study. MG was responsible for conceptualising this study, drafting and editing this manuscript. All authors contributed to the development of the search strategy. All authors have approved and contributed to the final written manuscript.

**Funding**

AG is a National Institute for Health Research (NIHR) academic clinical fellow (no grant number). FS was supported by a Cancer Research UK (C18281/ A29019) programme grant (the Integrative Cancer Epidemiology Programme), EV is supported by Diabetes UK (17/0005587). EV is also supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIS_2019_0009). RR is a de Peau VC research fellow at the University of Bristol (no grant number). JH supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol (no grant number), the NIHR Applied Research Collaboration West at University Hospitals Bristol and Weston NHS Foundation Trust (no grant number) and is an NIHR Senior Investigator (no grant number). MG is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust (grant number 202530/22/2). For the purpose of open access, the author has applied a CC BY public copyright licence to any author accepted manuscript version arising from this submission. The views expressed in this publication are those of the author(s) and not necessarily those of Wellcome, NIHR, the NHS or Department of Health.

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/).

**ORCID iDs**

Alexander Gormley [http://orcid.org/0000-0002-6228-9928](http://orcid.org/0000-0002-6228-9928)
Charlotte Richards [http://orcid.org/0000-0002-4624-1155](http://orcid.org/0000-0002-4624-1155)
Barry Main [http://orcid.org/0000-0003-0622-805X](http://orcid.org/0000-0003-0622-805X)
and community health and social care drug use alcohol and smoking datasets/adultdrinkinghabits [Accessed 01 Mar 2021].

5 Wotton CJ, Yeates DGR, Goldacre MJ. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia 2011;54:527–34.

6 Stott-Miller M, Chen C, Chuang S-C, et al. History of diabetes and risk of head and neck cancer: a pooled analysis from the International head and neck cancer epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2012;21:294–304.

7 Vilaseca I, Fuster G, Avilés-Jurado F-X. The impact of diabetes in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2020;28:107–11.

8 Régro DF, Elias ST, Amato AA, et al. Anti-Tumor effects of metformin on head and neck carcinoma cell lines: a systematic review. Oncol Lett 2017;13:554–66.

9 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.

10 Koivula RW, Heggie A, Barnett A, et al. Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the Iml direct Consortium. Diabetologia 2014;57:1132–42.

11 Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40–50.

12 Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6:97–106.

13 Dombrowski SU, Knittle K, Avenell A, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014;348:g2646. ARTN g2646.

14 Gray LJ, Cooper N, Dunkley A, et al. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes Rev 2012;13:483–98.

15 Yanovski SZ, Yanovski JA. Long-Term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74–86.

16 Corbin LJ, Timpson NJ. Body mass index: has epidemiology started to break down causal contributions to health and disease? Obesity 2016;24:1630–8.

17 Maasland DHE, van den Brandt PA, Kremer B, et al. Body mass index and risk of subtypes of head-neck cancer: the Netherlands cohort study. Sci Rep 2015;5:17744.

18 Gaudet MM, Kitahara CM, Newton CC, et al. Anthropometry and head and neck cancer: a pooled analysis of cohort data. Int J Epidemiol 2015;44:673–81.

19 Stott-Miller M, Chen C, Schwartz SM. Type II diabetes and metabolic syndrome in relation to head and neck squamous cell carcinoma risk: a SEER-Medicare database study. Cancer Epidemiol 2013;37:428–33.

20 Kao L-T, Hung S-G, Kao P-F, et al. Inverse association between statin use and head and neck cancer: population-based case-control study in Han population. Head Neck 2019;41:1193–8.

21 Yen Y-C, Lin C, Lin S-W, et al. Effect of metformin on the incidence of head and neck cancer in diabetics. Head Neck 2015;37:1268–73.

22 Ramteke P, Deb A, Shepal V, et al. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers 2019;11. doi:10.3390/cancers11091402. [Epub ahead of print: 19 09 2019].

23 Covidence. Covidence - Better systematic review management 2021, 2021. Available: https://www.covidence.org/ [Accessed 13 Sep 2021].

24 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.

25 World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia 2006, 2021. Available: https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf [Accessed 01 Mar 2021].

26 World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus 2011, 2021. Available: https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf [Accessed 01 Mar 2021].

27 World Health Organization. Obesity and overweight 2021, 2021. Available: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Accessed 01 Mar 2021].

28 British medical Journal. hypercholesterolemia 2019, 2021. Available: https://bestpractice.bmj.com/topics/en-us/170 accessed 28.03.2021

29 Organization WH. Hypertension 2021, 2021. Available: https://www.who.int/news-room/fact-sheets/detail/hypertension [Accessed 13 Sep 2021].

30 Organization WH. International statistical classification of diseases and related health problems (ICD) 2021, 2021 [Accessed 13 Sep 2021].

31 DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986;7:177–88.

32 Uo B. The ROBINS-E tool (Risk Of Bias In Non-randomized Studies - of Exposures) 2021, 2021. Available: http://www.bristol.ac.uk/population-health-sciences/centres/cresyda/barr/riskofbias/robins-e/ [Accessed 13 Sep 2021].